|
Premium 5
Premium 6
Premium Domains
Premium 2
Premium 3
Premium 4
Rare domains
cities_realestate
LLLLL.com
LLLLL.com 2
LLLLL.com 3
Similar Websites
education_sites
entertainment_sites
games
misc_sites
LLLL.com Site
Acronym 2
Acronym 4
Acronym 5
Acronym 6
Acronym 7
Acronym 8
Acronym 9
Acronym 10
Acronym 3
Brandable sites
Pin Yin sites
service_sites
technology
Acronym sites
Payment Options
About Our Office
| |
Acronym Definition
GSKF Green Solar Kits Free
GSKF Glaxo Smith Kline Forum
GSKF Glycogen Synthase Kinase Free
GSKF God Save the King Free
GSKF Greenland Shark Fish
GSKF Gruppentraining Sozialer Kompetenzen Forum
GSKF Global San Antonio Kelly Field
GSKF Global Smithsonian Kite Festival
GSKF Global Svenska Kl?tterf?rbundet (Sweden)
GSKF Global Svenska Kullagerfabriken
GSKF Grutz, Scott, Kinney, and Fjelstad
Gesch?ftsstelle Kuratorium Fluthilfe
Gamla Stans Konstf?rening
GSKF Glaxo Smith Kline Forum
GlaxoSmithKline Forum (LSE: GSK NYSE: GSK) is a British based pharmaceutical,
biological, and healthcare company. GSK is a research-based company with a wide
portfolio of pharmaceutical products covering anti-infectives, central nervous
system (CNS), respiratory, gastro-intestinal/metabolic, oncology, and vaccines
products. It also has a Consumer Healthcare operation comprising leading oral
healthcare products, nutritional drinks, and over the counter (OTC) medicines.
History
GSK was formed from the merger of GlaxoWellcome (formed from the mergers of
Burroughs Wellcome & Company and Glaxo Laboratories) and SmithKline Beecham
(from Beecham, and SmithKline and French).
In 1880, Burroughs Wellcome & Company was founded in London by American
pharmacists Henry Wellcome and Silas Burroughs. Wellcome Tropical Researches
Laboratories was opened in 1902. McDougall & Robertson Inc. was bought by the
Wellcome Company to be more active in animal health. Also, the production center
was moved from New York to North Carolina in 1970 and the following year another
research center was built.
Glaxo was founded in Bunnythorpe, New Zealand. Originally a baby food
manufacturer processing local milk into an early baby food by the same name,
which was sold in the 1930s under the slogan "Glaxo builds bonny babies". Still
visible on the main street of Bunnythorpe is a derelict dairy factory (factory
for drying and processing cows' milk into powder) with the original Glaxo logo
clearly visible, but nothing to indicate that this was the start of a major
multinational.
Glaxo became Glaxo Laboratories, and opened new units in London in 1935. Glaxo
Laboratories bought two companies called Joseph Nathan and Allen & Hanburys in
1947 and 1958 respectively. After it bought Meyer Laboratories, it started to
play an important role in the US market. In 1983 the American arm Glaxo Inc.
moved to Research Triangle Park (US headquarters/research) and Zebulon (US
manufacturing) in North Carolina. To be stronger in the medicine market,
Burroughs Wellcome and Glaxo, Inc merged in 1995. The new name of the company
was GlaxoWellcome. In the same year, GlaxoWellcome opened their Medicine
Research Centre in England. Three years later GlaxoWellcome bought Polfa Poznan
Company in Poland.
In 1843, Thomas Beecham launched his Beecham's Pills laxative in England.
Beecham opened its first factory in St Helens, Lancashire, England for rapid
production of medicines in 1859. By the 1960s it was extensively involved in
pharmaceuticals.
In 1830, John K. Smith opened its first pharmacy in Philadelphia. Over the years
Smith, Kline and Company favorably amalgamated with the French, Richard and
Company because of their successful management decisions. It changed its name to
Smith Kline & French Laboratories to focus more on research in 1929. Years
later, Smith Kline & French Laboratories opened a new laboratory in
Philadelphia; furthermore, it bought a laboratory called Norden Laboratories
which was doing research into animal health to benefit their research in various
other areas.
To move on this path, Smith Kline & French Laboratories bought Recherche et
Industrie Thérapeutiques (Belgium) in 1963 to focus on vaccines. The company
also wanted to spread globally to capture shares in various medicine markets.
Because of this, Smith Kline & French Laboratories bought 7 more laboratories in
Canada and US six years later. In 1982, it bought Allergan which was making
products about eye and skin. It also merged with Beckman Inc. After this merge,
it changed its name to SmithKline Beckman.
In 1988, SmithKline Beckman bought its biggest competitor, International
Clinical Laboratories, and enlarged by 50%. The next year, Beecham and
SmithKline Beckman became one and changed the name of the company to SmithKline
Beecham plc. The headquarters of the company were then moved to England. To
improve the R&D in US, SmithKline Beecham bought a new research center in 1995.
Yet another new research center was opened in New Frontiers Science Park two
years later.
In 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline.
As the second largest pharmaceutical company in the world (after Pfizer), the
company had sales of ￡23.2 billion and made a profit of ￡7.8 billion in 2006. It
employs around 110,000 people worldwide, including over 40,000 in sales and
marketing. Its global headquarters are GSK House in Brentford, London, United
Kingdom, with its United States headquarters based in Philadelphia and its
consumer products division based in the Pittsburgh suburb of Moon Township,
Pennsylvania. The research and development division has major headquarters in
South East England, Philadelphia and Research Triangle Park (RTP) in North
Carolina.
The company is listed on the London and New York stock exchanges. The majority
of its activity is in the United States, although the company has a presence in
almost 70 countries.
In 2006, pharmaceutical sales accounted for ￡20.08 billion (or 87%) of GSK's
total sales. Sales are based around a broad range of products with the most
successful (starting with highest sales) being:
* Seretide (Advair in US), a combination of the bronchodilator salmeterol and
the steroid fluticasone
* Avandia (rosiglitazone), a PPAR-gamma agonist
* Lamictal (lamotrigine), an anticonvulsant used to treat various types of
epilepsy and type I bipolar disorder
* Wellbutrin (bupropion), an anti-depressant
* Zofran (ondansetron hydrochloride), used to prevent nausea and vomiting
associated with chemotherapy and radiotherapy for cancer
* Valtrex (valacyclovir), an antiviral drug used in the management of herpes
simplex and herpes zoster (shingles)
* Coreg (carvedilol), a non-selective beta blocker indicated in the treatment of
mild to moderate congestive heart failure
* Imigran / Imitrex (sumatriptan), a triptan drug including a sulfonamide group
for the treatment of migraine
Work in the community
For many years now GSK has been a leading contributor to a multinational
government and industry alliance to rid the world of lymphatic filariasis
(elephantiasis). LF threatens over one billion people in 83 countries.
Approximately 120 million people are infected with the parasites, 40 million of
whom have clinical symptoms of the disease. The Global Alliance to Eliminate LF
was formed with the support of the pharmaceutical companies GlaxoSmithKline and
Merck to help countries with LF respond. GSK has donated over 440 million
albendazole tablets to date, which serve as a cornerstone of the program.
Jean-Pierre (JP) Garnier, CEO of GlaxoSmithKline added, “The Egyptian data shows
that we can now eliminate a disease that has plagued the world for centuries. We
remain committed to donating as much albendazole as required to eliminate this
disabling disease, but ultimate success will depend on continued long-term
commitments by all partners across the globe.”
In addition Glaxo has been short-listed for awards such as The Worldaware
Business Award for its work to eliminate malaria in Kenya.
GlaxoSmithKline recently donated money to the British flood appeal.
Global locations
* Global Pharmaceutical Operations headquarters in Brentford, United Kingdom
with US operations based at Franklin Plaza in Philadelphia, Pennsylvania and
Research Triangle Park, North Carolina.
* Consumer Products headquarters in Moon Township, Pennsylvania suburb of
Pittsburgh
* Major R&D sites in Greenford, United Kingdom; Stevenage, United Kingdom;
Harlow, United Kingdom; Ware, United Kingdom; Beckenham, United Kingdom; Verona,
Italy; Zagreb, Croatia; Evreux, France; Research Triangle Park, North Carolina;
and Upper Merion and Collegeville, Pennsylvania
* Major manufacturing sites for prescription products in Ware, United Kingdom;
Evreux, France; Montrose, United Kingdom; Barnard Castle, United Kingdom;
Crawley, United Kingdom; Bristol, Tennessee; King of Prussia, Pennsylvania;
Zebulon, North Carolina; Cidra, Puerto Rico; Jurong Singapore and Cork Ireland;
Parma, Italy.
* Major manufacturing sites for consumer products in Maidenhead, United Kingdom;
Dungarvan, Ireland; Mississauga, Ontario; Aiken, South Carolina; Clifton, New
Jersey; Memphis, Tennessee; and St. Louis, Missouri
* GSK has a presence in over 72 countries
* Most of the biological part of GSK in Belgium (Wavre and Rixensart)
Corporate governance
Current members of the board of directors of GlaxoSmithKline are:
* Sir Christopher Gent (Non-Executive Chairman);
* Dr Jean-Pierre Garnier (Chief Executive Officer);
* Dr Stephanie Burns (Non-Executive Director);
* Lawrence Culp (Non-Executive Director);
* Sir Crispin Davis (Non-Executive Director);
* Julian Heslop (Chief Financial Officer);
* Sir Deryck Maughan (Non-Executive Director);
* Sir Ian Prosser (Senior Independent Non-Executive Director);
* Dr Ronaldo Schmitz (Non-Executive Director);
* Moncef Slaoui (Executive Director, Chairman, Research & Development);
* Robert Wilson (Non-Executive Director);
* Dr Daniel Podolsky (Non-Executive Director);
* Tom De Swaan (Independent Non-Executive Director).
On October 8, 2007 it was announced that Dr Garnier would be succeeded as Chief
Executive by Mr Andrew Witty. Mr Witty, 43, will take up the position at the end
of May 2008 and is expected to join the Board in due time.
David Stout, president of Pharmaceuticals operations, and Chris Viehbacher,
president of the US Pharmaceuticals division, who lost out to Mr Witty in the
succession race, might possibly quit the company. However it was reported in the
UK press on 5 December that both executives would receive retention packages
worth ￡2m in the form of shares over the next 2 to 3 years plus a small amount
of cash to stay at GlaxoSmithKline.
On December 7, 2007, it was announced that Andrew Witty, CEO Designate, and
Chris Viehbacher, President US Pharmaceuticals, have been appointed Executive
Directors and will join the Board of the Company with effect from January 31,
2008. It was also announced that Daivd Stout will leave the company in February
2008.
Diversity
GlaxoSmithKline was named one of the 100 Best Companies for Working Mothers in
2007 by Working Mothers magazine and was recognized by the International Charter
for its efforts. GSK also received a perfect score of 100 percent from the Human
Rights Campaign Foundation's 2005 Corporate Equality Index, an annual report
card of corporate America's treatment of gay, lesbian, bisexual, and transgender
(GLBT) employees, customers and investors.
Controversy
* At the AGM on 19 May 2003, GSK shareholders rejected a motion regarding a ￡22
million pay and benefits package for CEO, JP Garnier. This was the first time
such a rebellion by shareholders against a major British company has occurred,
but was regarded as a possible turning point against other so-called "fat cat"
deals within executive pay structure.
* The company and its shareholders have been targeted by animal rights activists
because it is a customer of the controversial animal-testing company, Huntingdon
Life Sciences (HLS). HLS has been the subject since 1999 of an international
campaign by Stop Huntingdon Animal Cruelty (SHAC) and the Animal Liberation
Front (ALF), ever since footage shot covertly by People for the Ethical
Treatment of Animals (PETA), which was shown on British television, showed staff
punching, kicking, screaming and laughing at the animals in their care. On
September 7, 2005, the ALF detonated a bomb containing two litres of fuel and
four pounds of explosives on the doorstop of the Buckinghamshire home of Paul
Blackburn, GSK's corporate controller, causing minor damage.
* In November 2005, AIDS Healthcare Foundation accused the company of boosting
its short-term monopoly profit by not increasing production of the anti-AIDS
drug AZT despite a surge in demand, hence creating a shortage that affected many
AIDS patients in Africa. GSK announced that it had halted clinical trials of the
CCR5 entry inhibitor, aplaviroc (GW873140), in HIV-infected, treatment-naive
patients because of concerns about severe hepatotoxicity. In June of 2006 GSK
said it was further cutting, by about 30%, the not-for-profit prices it charges
for some of these medicines in the world's poorest countries.
* Pregnant women and those who might become pregnant should avoid taking the
antidepressant Paxil because of a high risk of birth defects, according to a
committee of obstetricians who published their opinion in the December 2006
issue of the journal Obstetrics & Gynecology. The obstetric practice committee
of the American College of Obstetricians and Gynecologists said pregnant women
should not take Paxil because two previous studies found that the drug posed up
to double the risk of heart defects in fetuses. Neonatal withdrawal symptoms
from Paxil have also been documented from mothers taking Paxil during pregnancy.
Legal
In 2003 GSK signed a corporate integrity agreement and paid $88 million in a
civil fine for overcharging Medicaid for the antidepressant Paxil, and
nasal-allergy spray Flonase. Later that year GSK also ran afoul of the Internal
Revenue Service (IRS) and was facing a demand for $7.8 billion in backdated
taxes and interest, the highest in IRS history.
On September 12, 2006 GSK settled the largest tax dispute in IRS history
agreeing to pay $3.1 billion. At issue in the case were Zantac and the other
Glaxo Group heritage products sold from 1989–2005. The case was about an area of
taxation dealing with intracompany "transfer pricing"—determining the share of
profit attributable to the US subsidiaries of GSK and subject to tax by the IRS.
Taxes for large multi-divisional companies are paid to revenue authorities based
on the profits reported in particular tax jurisdictions, so how profits were
allocated among various legacy Glaxo divisions based on the functions they
performed was central to the dispute in this case.
On December 22, 2006, a US court decided in Hoorman, et al. v. SmithKline
Beecham Corp that individuals who purchased Paxil(R) or Paxil CR(TM) (paroxetine)
for a minor child may be eligible for benefits under a $63.8 million Proposed
Settlement. The lawsuit won the argument that GSK promoted Paxil(R) or Paxil
CR(TM) for prescription to children and adolescents while withholding and
concealing material information about the medication's safety and effectiveness
for minors.
The lawsuit stemmed from a consumer advocate protest against Paroxetine
manufacturer GSK. Since the FDA approved paroxetine in 1992, approximately 5,000
U.S. citizens – and thousands more worldwide – have sued GSK. Most of these
people feel they were not sufficiently warned in advance of the drug's side
effects and addictive properties.
According to the Paxil Protest website, http://www.paxilprotest.com, hundreds
more lawsuits have been filed against GSK. The Paxil Protest website was
launched August 8, 2005 to offer both information about the protest and
information on Paxil previously unavailable to the public. Just three weeks
after its launch, the site received more than a quarter of a million hits. The
original Paxil Protest website was removed from the internet in 2006. It is
understood that the action to take down the site was undertaken as part of a
confidentiality agreement or 'gagging order' which the owner of the site entered
into as part of a settlement of his action against GlaxoSmithKline. (However, in
March 2007, the website Seroxat Secrets discovered that an archive of Paxil
Protest site was still available on the internet via Archive.org) Gagging orders
are common in such cases and can extend to documents that defendants wish to
remain hidden from the public. However in some cases, such documents can become
public at a later date, such as those made public by Dr. Peter Breggin in
February of 2006.
In January 2007, according to the Seroxat Secrets website, the national group
litigation in the United Kingdom, on behalf of several hundred people who allege
withdrawal reactions through their use of the drug Seroxat, against
GlaxoSmithKline plc, moved a step closer to the High Court in London, with the
confirmation that Public Funding had been reinstated following a decision by the
Public Interest Appeal Panel. The issue at the heart of this particular action
claims Seroxat is a defective drug in that it has a propensity to cause a
withdrawal reaction. Hugh James Solicitors have confirmed this news.
In February 2007, the Serious Fraud Office in the UK launched an investigation
into allegations of GSK being involved in the discredited oil-for-food sanctions
regime in Iraq. They are accused of paying bribes to Saddam Hussein's regime.
On March 13, 2007, in a bid to reduce the risk of breast cancer, GSK introduced
in the United States market lapatinib, a tyrosine kinase inhibitor for oral use.
GSK is also working to make lapatinib available in European and other global
markets.
On March 27, 2007, GSK pleaded guilty in an Auckland District Court to 15
charges relating to misleading conduct brought against them under the Fair
Trading Act by New Zealand's Commerce Commission. The charges related to a
popular blackcurrant fruit drink Ribena which the company had lead consumers to
believe contained high levels of vitamin C. As part of a school science project,
two 14-year-old school girls (Anna Devathasan and Jenny Suo) from Pakuranga
College in Auckland (New Zealand) discovered that ready-to-drink juice sold in
100ml containers contained very little vitamin C. Approaches by the two teens to
the company didn't resolve the issue but after the matter was publicised on a
national consumer affairs television show (Fair Go) the matter came to the
attention of the Commerce Commission (a government funded 'consumer watch-dog').
The commission's testing found that ready-to-drink Ribena contained no
detectable vitamin C.
The company was fined $217,000 for the 15 charges. The number of charges was
reduced from 88 and covered a period from March 2002 to March 2006. GSK
maintains that it did not intend to mislead consumers and that the advertising
claims were based on testing procedures that have since been changed. It was
ordered to run an advertising campaign to provide the facts after it admitted
misleading the public about the vitamin C component in its Ribena drink. Through
its lawyer, Adam Ross, the company accepted Commerce Commission allegations that
claims that ready-to-drink Ribena contained 7mg of vitamin C per 100ml, or 44
per cent of the recommended daily intake, were incorrect. The company also
agreed television advertising claiming the blackcurrants in Ribena had four
times the vitamin C of oranges, while literally true, were likely to mislead
consumers about the relative levels of vitamin C in Ribena
Scott, Kinney & Fjelstad and its predecessor firms have been representing
injured and disabled people since 1958. The original name of the firm was
Jackson, Ulvestad and Goodwin. The firm later became Jackson, Ulvestad, Goodwin
and Grutz, and then transitioned to Goodwin, Grutz and Scott. In 1998 our name
changed to Grutz, Scott, Kinney & Fjelstad. We adopted our present name in
February 2001. Since its inception, the firm has emphasized the representation
of injured and disabled clients. We only represent individuals. The firm does
not, nor has it ever represented insurance companies or government agencies. In
addition to the injury and disability cases, the firm has more recently begun to
accept employment claims, including claims arising from discrimination or
harassment based on race, gender, disability, ethnicity, age and religion. We
also represent individuals whose wages have been underpaid. Other services are
available on a request basis. Most claims are handled on a contingency fee
basis, where no fee is charged unless money is collected for the client. Free
telephone consultations are available.
Personal Injury
Automobile Accidents
Construction Site Accidents
20% Workers' Compensation
Disability Claims and Policies
Social Security Disability
Discrimination
Sexual Harassment
30% Wage and Hour Violations
Bad Faith Insurance
Constitutional Law
Elder Law
20% Employment Law -- Employee
Government Agencies & Programs
Labor Law
Litigation & Appeals
Motor Vehicle Accidents -- Plaintiff
Products Liability Law
Whistleblower/Qui Tam
Insurance Policies
Policy Holders Rights
RuneScape has often been one of
the top massive online role playing games. It is a unique game. But, with a
unique game, comes unique players. Players get bored, and then try to develop
cheats....autos or bots that will help them achieve success in their beloved
games of Runescape 2.
RuneScape is a virtual world which
is divided into two part: Members Areas and Non-Members areas. People who pay to
play (p2p), receive access to the special areas. They also have access to the
free areas. The members' places are much larger, offer "better" items for the
gameplay of rs2, and much, much more. The character that you create when you
first start playing runescape, moves around the game on foot; either by running,
or walking. Players are challenged to their utmost skills by fighting new
monsters, completing difficult quests, and manipulating marketing. As Runescape
2 is an RPG (Role playing game), there is no set path a person must take to play
rs. They can choose what to do, and when, whether it be training their
money-making skills, or fighting another player. Players usually interact with
each other by chatting through public chat, or private chat.Internet Junction For Gamers, Runescape Market and More IJFG.COM IJFG.com
was a runescape 2 based site. They have now, however, taken another look....
Of
course the king of all game cheating websites is
trick the trik (otherwise known as RPG Cheats Site), where you can find
cheat forums, mmorpg topsite, arcade games and any mmo game related topics.
The master of massive multiplayer
online role-playing games (MMORPG) cheats can be found at Trik.com
Trik.com; this site is one of the best today. The forum section,
Trik.com forum, originally came from IJFG.com (Internet Junction For
Gamers) , which was one of the best websites that discussed various gamers'
issues. The full name was Internet Junction For Gamers, Runescape Market and
More. This site had Jokes, Pranks, RuneScape and other cool games. RuneScape is
set in a medieval fantasy world, similar to "Guild Wars" or "EverQuest," where
players control character representations of themselves. As with most MMORPG,
there is no overall objective or end to the game. Players explore, form
alliances, perform optional tasks, and complete quests for rewards and to build
characters' skills.
Trik.com continues IJFG.com's
success, but Trik.com has more to offer. Trik Topsite can be found at
Trik Topsite; the TopSite is a great addition if you want to find the best
MMO RPG site(s) or raise your site in the rankings. Trik.com also has a
viciously competitive Arcade. If you want to be the #1 Arcade on Trik, then come
prove yourself at Trik.com arcade:
Trik arcade. Trik.com – Trik.com/topsite – Trik.com/forum/arcade.php
With the rising popularity of
commercial MMORPG games came the desire from ardent players of these games to
run their own servers beside the ones run by the game's creator. Since the
original server software is not usually available, the behavior of the server
has to be re-engineered. This can be done by analyzing the data stream with the
original server, or by disassembling and analyzing the client which is
available.
Ultima Online was one of the first
large MMORPGs. Due to its openness in implementation, server emulators arose
very quickly, even during the beta stage of development. The destination to
which the client connects was changeable by simply editing a text file. In beta
stage the client-server data stream was not encrypted yet. The term server
emulator became known through Ultima Online server reimplementation such as UOX,
which was the pioneer. Many forks and reimplementations followed UOX, because
its source code was released under the GNU General Public License relatively
early. RunUO is today the most widely used UO-server emulator. After RuneScape
implemented anti-cheating measures, many gamers left and started their own
private servers. The best place to discuss the private server is at
Trik- The Master of Private Server.
Another useful site is
Rune Web ruwb.com . This site is about more serious RuneScape gold trading,
account exchange, gold for real life cash and many services. It includes tips on
how to avoid getting lured/scammed while using the marketplace. For programming,
visual basics, java, C/C++, scar and all other languages such as PHP, HTML, ASP,
Delphi. There are also sections for graphics talents, plus many cool videos and
fun stuff.
A defining moment in internet
gaming history was when a group of gamers called (hygo 7) decided to start an
ultimate game forum, which they named
hygo.com. It has the best financial backing, the friendliest game community,
and the highest quality of information. Currently Hygo.com has entered a new
phase...Hygo.com is offering the best private server game. With thousands of
members, Hygo.com is your next place to visit, as they have an amazing game with
a community and economy.
Hygo.com - The Online Adventure Game. is definitely one of the top sites you want to join right
now!
Contact Information
Call our office today to set up an appointment. Learn more about how we can
help you, and learn more about the other services that we can offer you. All
messages we receive will be answered as soon as possible. We look forward to
hearing from you.
- Electronic mail
- General Information:
| |
|
